GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Tangible Book per Share

XOMA (XOMA Royalty) Tangible Book per Share : $4.68 (As of Dec. 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. XOMA Royalty's tangible book value per share for the quarter that ended in Dec. 2024 was $4.68.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


XOMA Royalty Tangible Book per Share Historical Data

The historical data trend for XOMA Royalty's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Tangible Book per Share Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.69 12.53 9.50 7.71 4.68

XOMA Royalty Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.71 7.07 8.57 7.21 4.68

Competitive Comparison of XOMA Royalty's Tangible Book per Share

For the Biotechnology subindustry, XOMA Royalty's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Price-to-Tangible-Book falls into.


;
;

XOMA Royalty Tangible Book per Share Calculation

XOMA Royalty's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(81.921-0.049-25.909)/11.952
=4.68

XOMA Royalty's Tangible Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(81.921-0.049-25.909)/11.952
=4.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


XOMA Royalty  (NAS:XOMA) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


XOMA Royalty Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Joseph M Limber director ACLARA BIOSCIENCES INC, 1288 PEAR AVE, MOUNTAIN VIEW CA 94043
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555